(Q34856701)

4 August 2017

1 reference

title

Osteoporosis during androgen deprivation therapy for prostate cancer (English)

1 reference

4 August 2017

0 references

1 reference

Matthew R Smith

1

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

4 August 2017

1 reference

4 August 2017

volume

60

1 reference

4 August 2017

issue

3 Suppl 1

1 reference

4 August 2017

page(s)

79-85; discussion 86

1 reference

The structural basis of bone fragility in men.

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

The diagnosis of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

The predictive value of forearm bone mineral content measurements in men.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Low bone mineral density in hormone-naïve men with prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Cross-sectional assessment of age-related bone loss in men: the MINOS study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Comparative tolerability of drug therapies for hypercalcaemia of malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Posterior-anterior and lateral dual-energy x-ray absorptiometry for the assessment of vertebral osteoporosis and bone loss among older men

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Dual energy radiography versus quantitative computer tomography for the diagnosis of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

The diagnostic value of bone scintigraphy in patients with low back pain

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

1 reference

7 January 2021

Osteoporosis in men with hyperprolactinemic hypogonadism

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Osteoporosis in men with idiopathic hypogonadotropic hypogonadism

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Progressive osteoporosis during androgen deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

How is androgen-dependent metastatic prostate cancer best treated?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Endocrine profiles during administration of the new non‐steroidal anti‐androgen Casodex in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Treatment of locally advanced prostate cancer--a new role for antiandrogen monotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden)

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

Alendronate for the Treatment of Osteoporosis in Men

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901579-0

7 January 2021

10.1016/S0090-4295(02)01579-0

Identifiers

DOI

1 reference

4 August 2017

1 reference